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Abstract
Background: Agent based models (ABM) are useful to explore population-level scenarios of disease spread and
containment, but typically characterize infected individuals using simplified models of infection and symptoms
dynamics. Adding more realistic models of individual infections and symptoms may help to create more realistic
population level epidemic dynamics.
Methods: Using an equation-based, host-level mathematical model of influenza A virus infection, we develop a
function that expresses the dependence of infectivity and symptoms of an infected individual on initial viral load, age,
and viral strain phenotype. We incorporate this response function in a population-scale agent-based model of
influenza A epidemic to create a hybrid multiscale modeling framework that reflects both population dynamics and
individualized host response to infection.
Results: At the host level, we estimate parameter ranges using experimental data of H1N1 viral titers and symptoms
measured in humans. By linearization of symptoms responses of the host-level model we obtain a map of the
parameters of the model that characterizes clinical phenotypes of influenza infection and immune response variability
over the population. At the population-level model, we analyze the effect of individualizing viral response in
agent-based model by simulating epidemics across Allegheny County, Pennsylvania under both age-specific and
age-independent severity assumptions.
Conclusions: We present a framework for multi-scale simulations of influenza epidemics that enables the study of
population-level effects of individual differences in infections and symptoms, with minimal additional computational
cost compared to the existing population-level simulations.
Background
Models of infectious disease epidemics, such as due to
influenza A virus, have proven useful for understanding
dynamics of disease transmission, vaccination strategies,
and are frequently used as a decision support tool by
public health officials. Single scale models of influenza
A virus have been developed both on the host-level and
on the population level in order to study epidemiological,
immune response and viral characteristics of influenza A
infection [1].
*Correspondence: slukens@nd.edu
1Department of Mathematics, University of Pittsburgh, Pittsburgh, PA, USA
9Department of Biological Sciences, University of Notre Dame, South Bend, IN,
USA
Full list of author information is available at the end of the article
On the population scale, continuous models based on
SIR (susceptible/infected/removed) approaches have been
used for large-scale epidemiological predictions [2]. Con-
tinuous SIR models assume homogeneous populations
and any model assumption about heterogeneity (such as
human characteristics, network structure, and environ-
mental factors) increases the number of equations and
parameters, necessitating changing the model structure
for any additional assumption. An alternative discrete
approach to the study of disease epidemics is through
agent-based models (ABM), where individuals are rep-
resented as autonomous agents whose infectious status
is followed in time. Population density, age-structure,
travel patterns and inter-individual contact patterns are
derived or inferred from available census and demo-
graphic data. The infection propagates in the population
according to disease transmission and duration rules,
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where inter-individual variability is represented in the
form of statistical distributions. Because ABMs evolve
individual agents, simulations require considerable com-
putational cost. Many large-scale collaborative networks
have developed and use large platform ABMs to make epi-
demiological predictions [3-6] and the impact of a variety
of mitigation strategies. ABMs have been used in studies
of school closure strategies [7,8], in determining the role
of subway travel in an epidemic [9], in the role of presen-
teeism on disease transmission in the workplace [10], and
in vaccine allocation [11,12].
Immuno-epidemiological models explore how host-
level immune response affects population-level epidemi-
ological patterns [13] and allow much finer tuning
of host-behavior, compared to population-level models.
The nested modeling approach embeds a mechanis-
tic model of host-pathogen disease dynamics into an
epidemiological model of infection by linking epidemio-
logical parameters such as transmission rate or duration of
infectiousness [14-16]. Immuno-epidemiological models
consider assumptions about acquired immunity to study
spread of infection [17-19] or host-parasite co-evolution
[14,20]. To account for heterogeneity in immune response,
SIR models may be refined to incorporate individual host
response through different linking mechanisms. Under-
standing the biological mechanisms underlying these vari-
ations in host response is important for estimating disease
parameters and for designing optimal prevention strate-
gies [21,22].
Symptoms of influenza infection include fever, sore
throat, chills, and cough, and have been attributed to the
immune response to viral infection [23-26]. Clinical mark-
ers related to disease and disease-severity, largely due to
host-immunity factors and prior exposures, are referred
to as clinical phenotypes. Mathematical models of within-
host influenza A infection have been used in estimation
of kinematic parameters such as infection and clearance
rates of the virus, as well as in prediction of dynamics and
drug therapy strategies for individual infection [27,28],
yet have not been used to provide a mechanistic basis
for varying disease phenotypes. Immuno-epidemiological
modeling could be used to account for variability in clini-
cal phenotype and evaluate the impact of symptom-based,
biologically-based, and potentially behavior-basedmitiga-
tion strategies at the population level.
A key challenge in deriving a realistic description of
within-host responses is lack of data at the host-level.
Human data is available from volunteer challenge stud-
ies where volunteers are inoculated intranasally, tend
to be young (ages 18-35), healthy, and pre-screened for
existing immunity to the experimental IAV strain. For
H3N2 it has been shown that illness following intranasal
inoculation is milder than illness following aerosol inocu-
lation, manifested by shorter duration of cough and fever
[29]. Mechanisms of transmission of naturally acquired
infection include contact transmission, droplet spray
transmission, and aerosol transmission. Therefore, using
a host-level model to predict individual response to
influenza infection requires altering model parameters
based on healthy volunteer data in a biologically meaning-
ful way.
Morbidity and mortality resulting from influenza infec-
tion is highest among the elderly (>65) and children. In
a study of pandemic H1N1 in Ontario Canada, recovery
was faster among patients under 18 years of age [30]. To
gain qualitative insight of how host-level dynamics are
varied as a function of age, animal studies prove to be use-
ful. A study between aged and adult mice infected with
sublethal doses of influenza virus (A/Puerto Rico/8/1934)
showed slower recovery and delay in immune system acti-
vation and virus clearance in aged mice [31]. Differences
in mouse response as a function of age provide insight
in how to vary baseline responses in a within-host model
across different age groups, while synthetic population
data sets provide reasonable age distributions across a
population [32,33].
Naive integration of awithin-hostmodel in a population-
level ABM requires the evaluation of a nonlinear system
of differential equations for each individual infected,
which is computationally prohibitive for realistically large
simulations. In this manuscript, we present a prototypi-
cal hybrid immuno-epidemiological ABM model linking
an equation-based within-host model and providing
mechanistically-based host variability to an agent-based
population level model. For outputs of the within-host
model we choose the infectivity and symptoms scores dur-
ing the time course of infection, which reflect likelihood
of transmission and stay-at-home behavior of an infected
individual. In this fashion, we can replicate existing
results from simulated epidemics, but we introduce addi-
tional flexibility in studying variation of host-response
at no additional computational cost. To eliminate com-
putational cost, we replace the exact response with an
approximation obtained by analyzing the most significant
response modes of the within-host model. Further, the
within-host model is simple to program and implement,
and can be used to represent within-host dynamics in a
variety of population-level platforms. We apply the hybrid
ABM model to study questions arising from individual
heterogeneity that cannot be addressed using a single
scale model. In particular, we examine the role of varying
severity of disease as a function of age on the dynamics
of simulated epidemics. We find that epidemiological
estimates such as attack rate and incidence are reduced
when differences in host response across age groups are
considered. Use of the immuno-epidemiological ABM
model opens up many possibilities regarding the realistic
impact of influenza on populations with different contact
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The data set consists of viral load and symptom data
from five previously published human volunteer studies
conducted between 1995 and 1999 for 84 total individ-
uals infected with A/Texas/36/91 (H1N1) [23,24,34-36].
Of these studies, only one [35] (n=17) does not contain
symptom data. The viral titers across the five studies are
all reported as averages across individuals in the respec-
tive studies in units of log10 TCID50/mL. To adjust the data
across studies, we used mixed-effects modeling to com-
pute a vertical shift for each study (random-effect), assum-
ing that the distance between each curve is minimized.
We computed weighted means and standard deviations
(fixed-effect) on the shifted data.
In all studies, symptom scores were measured twice a
day, and averaged. Across studies, 65 of the 67 individuals
with symptoms data experienced at least one symptom.
While similar symptoms were scored, their measurements
were on different scales across studies. As done in [37], we
scaled each study curve to its maximum clinical score. The
summary curves for both titer and symptoms were calcu-
lated as a weighted average with weights as the number of
individuals considered in each study. Data is summarized
in the Additional file 1.
Overview of the immuno-epidemiological ABMmodel
We describe the process in which we link an equation-
based model of within-host influenza A dynamics to a
population scale ABM. A diagram of the procedure is
shown in Figure 1. A collection of agents representing the
population interacts within the simulation environment,
transmitting infection in the process. Knowledge of the
within-host immune response is used to determine the
response of each agent to infection. Within each host, the
immune response is reduced using principal component
analysis (PCA) to identify significant directions in param-
eter space that describe most of the variability in immune
response. Response surface analysis (RSA) captures the
relationship between input (now simplified to two prin-
cipal components) and model response (infectivity and
symptoms) as an algebraic equation. Randomization over
the principal components is used to generate popula-
tion response variability. With this framework in place,
we simulate disease outbreaks to see how changes at the
within-host level affect a simulated epidemic in Allegheny
County, PA.
Estimation of parameters for virus/symptomsmodel
We enhanced a target-cell limited ordinary differential
equation (ODE)model first proposed by Baccam et al. [38]
to model viral and symptoms dynamics within a host with
an additional term to incorporate symptoms dynamics:
V˙ = pI − cV , (1)
H˙ = −βHV , (2)
I˙ = kJ − δI, (3)
J˙ = βHV − kJ , (4)
˙ = θ I − a . (5)
A schematic of the model is shown in the left panel of
Figure 1(a). An individual is infected by an initial viral
load V (0) = V0, which infects target cells (H) of the
respiratory tract with infection rate β . Virus replicates
within latent phase cells (J), which after average rate of
time k become infectious (I) and shed virus at a rate p.
Infected cells die at rate δ, primarily through cell necro-
sis, which triggers productions of cytokines such as type
I interferons (IFN), interleukin(IL)-6, tumor necrosis fac-
tor (TNF)-α and IL-1 [39]. The novel contribution of
this model is the inclusion of a variable  quantifying
the intensity of systemic symptoms of influenza, such as
malaise and fever. Of all the variables of the model, it
is most reasonable to have systemic symptoms depen-
dent on infected cells, since both flu-like symptoms and
severity of systemic symptoms have been shown to be
correlated to cytokine levels [40,41], particularly IL-6 and
IFN-α/β [23,24,42], and inflammatory cytokines are, in
turn, produced by infected cells. It has also been noticed
experimentally that the number of days of viral shedding
is correlated with cytokine levels, severity of symptoms,
and mucus weight [43,44]. While resolution of symptoms
is a complex process, we assume a constant decay rate
a. Model trajectories include viral load and symptoms
scores, which are used as determinants of infectivity and
symptomaticity in the population level simulation and
represent state variables corresponding to data. We use
Bayesian inference to construct an ensemble of models
consistent with the data in order to explore the parame-
ter space associated with our model and data. We sample
the Bayesian posterior density P(α|D) using a Markov
Chain Monte Carlo (MCMC) method with parallel tem-
pering [45-48]. Ensemble modeling results in a collection
of trajectories consistent with the data, in which each tra-
jectory corresponds to a parameter set from the posterior
distribution.
Abstraction of the within-host model for population-level
evaluation
The ensemble of model parameters α sampled from the
posterior distribution P(α|D) is used to determine how
the immune response depends on model parameters, and
how the response varies over the population [49,50]. As
large ranges of parameter values may all fit the data, we
seek to identify directions in parameter space in which
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Figure 1 Schematic diagram of the hybrid model. (a) Naive combination of equation based model of virus and symptoms dynamics of influenza
A infection with a population level model. Clinical phenotypes of infection are input into the host-level model, which is integrated numerically and
returns symptoms and infectivity of an infected individual to use for simulation of an epidemic. (b) In the hybrid ABMmodel response surface
replaces host-level ODE model.
the model behavior is tightly constrained in order to make
predictions. The ensemble of parameters can be charac-
terized using the covariance matrix  = cov(α), or the
Hessian matrix of the cost manifold at a global mini-
mum in parameter space; these two matrices are related
as H ≈ −1. A singular value decomposition, or PCA, of
this approximated Hessian provides principal directions
in parameter space corresponding to maximum changes
in the model with respect to the cost function, here
represented by total deviance from empirical virus and
symptom values at each day during infection. We use the
principal directions to vary parameter values for model
evaluation, and define the hyper-plane P = span{d1, d2}
as the plane in parameter space spanned by the two lead-
ing principal directions. The computational domain is
a discretization of the box [−0.5, 0.5]× [−0.5, 0.5]⊂ P
into a 20 by 20 grid. We select a random sub-sample
of 1,000 parameter sets from the ensemble, which char-
acterizes the “origin” of the hyper-plane. For each point
on the grid, parameters are deviated from baseline along
two principal directions by a distance specified by the
grid coordinates. The deviated values are simulated in the
model (Equations 1-5) yielding viral loads and symptoms
responses for 11 days. The simulated median surface is
then parameterized by a quadratic polynomial, which has
the form
yˆ = b0 + b1x1 + b2x2 + b3x1x2 + b4x21 + b5x22. (6)
Population level model
The within-host representation is linked to the Frame-
work for Replication of Epidemiological Dynamics
(FRED) ABM software, an open source population-level
large scale modeling system developed by the University
of Pittsburgh Models of infectious Disease Agents Study
(MIDAS) Center of Excellence. We use data from the syn-
thetic population database, which is freely available and
based on 2005-2009 U.S. census data [32] from Allegheny
County, Pennsylvania. The data from the 1,164,879 agents
assigns characteristics and behaviors such as occupa-
tion and workplace or school [32,33] to each individual.
Each household is assigned a latitude/longitude coordi-
nate, income, size, and the sex, race, and age of household
occupants, representing the distribution of U.S. house-
holds. Behavior and daily routine of agents are based
on a set of assumptions that describe contact patterns
and movements of individuals. Individuals interact daily
with schools or workplaces, household, and neighborhood
networks. In each scenario, individuals contact infection
based on a fixed mean number of people per day. For
detailed descriptions on how agents interact and perform
daily routines, the reader is referred to [4,7,9-12,51].
At any time in FRED, each agent is in one of four
states: susceptible (S), exposed (E), infectious (I) and
recovered (R). We assume that individuals transition from
the exposed state to the infectious state when the com-
puted infectivity crosses a defined threshold. All agents
are initially susceptible to infection, and at t = 0 days,
100 random agents are initialized in the exposed state.
Contact with an infectious person has an assigned prob-
ability of transmission, which is further modulated by the
individual’s infectivity (See Additional file 1).
Results
Model ensemble
The marginals and correlation plots for the posterior dis-
tribution P(α|D) are shown in Figure 2 for a sample of 1
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Figure 2 Parameter distributions and correlations of model parameters. (a) One dimensional projections (marginal distributions) of posterior
distribution along each (log) parameter axis. Biological bounds constrain values of V0, c, δ and k. Other parameters are normalized against their
baseline value and shown in log scales. (b) Density plots of correlations of select parameter pairs of parameters.
million parameter values. Values for the best-fit parame-
ter set are provided in Table 1. Calculation of correlation
coefficients across the ensemble shows three parameter
pairs to be significantly correlated. Viral production (p)
and degradation rates (c) are highly correlated (with cor-
relation coefficient R = 0.90), as are symptoms onset (θ )
and clearance (a) terms (R = −0.85). A parameter pair of
interest are inoculum size (V0) and infection rate (β), with
correlation R = −0.80. To fit the data, either a small initial
viral load pairs with a fast infection rate for the viral tra-
jectory to reach the first data point, or a larger initial viral
load pairs with a slower infection rate.
Using a random sub-sample of 15,000 parameter sets
from the ensemble, statistical representation of trajec-
tories showing median, 25-75, and 5-95 percentiles of
variable values are plotted at each time point in Figure 3.
The model fits data well, including the variability in the
symptom response. There is variability across trajectories
in viral load during the first 2 days, due to the different
inoculum sizes V0 spanning several log scales and related
to the correlation between V0 and the infection rate.
Representing biological phenotypes
Singular value decomposition on the approximated Hes-
sian of the posterior distribution was performed to iden-
tify candidate directions. Due to the strong correlation of
the inoculum size V0 with the infection rate β revealed in
analysis on the ensemble, it is only necessary to vary one
of these two parameters (V0 and β) to achieve observable
differences and the model is more sensitive to changes in
infection rate. Therefore, we fix V0 associated with a given
parameter set and reduced the parameter space to seven
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Table 1 Parameter values
V0 β p c δ k θ a
Description Inoculum Infection Viral Viral Infected Latent Rate of Symptoms
size rate production clearance cell decay cell symptoms clearance
rate rate rate rate onset rate
Units TCID50 mL (TCID
−1
50 mL day
−1) TCID−150 mL day−1 (day−1) (day−1) (day−1) day−1[ S]−1 (day−1)
Baseline (α0) 0.02 0.083 4000 3 1.3 5 2.5 0.55
Lower Bounds 0.75e-5 β0/35 p0/35 8 0.5 2 θ0/35 a0/35
Upper Bounds 1 35β0 88p0 40 2 6 35θ0 35a0
Best fit 7.50e-6 0.0674 40356 8.00 1.364 3.684 2.75 0.498
The reported bounds are used for parameter estimation. Epithelial cells are scaled and hence have non-dimensional units. Symptoms are based on a symptoms score





dimensions. Variation in inoculum size is still present due
to the range of values sampled in the posterior distribu-
tion. Combined, directions one and two account for 89.2%
of the variability, while the other five components account
for the remaining. The leading two components give the
following directions in parameter space:
d1(α) = −0.19β + 0.037p − 0.094c − 0.94δ − 0.25k
+ 0.050θ − 0.059a, (7)
d2(α) = −0.22β − 0.39p + 0.36c + 0.096δ − 0.14k
− 0.12θ + 0.16a. (8)
Median trajectories and 69 percentile envelopes from
1,000 random parameter sets sampled from the ensem-
ble varied in each of these directions is shown in Figure 4.
The first direction d1 = d1(α) (Figure 4b) corresponds
to dynamics related to recovery from infection, and is
dominated by δ, the infected cell decay rate. Slower clear-
ance of infected cells results in prolonged viral load, and
more severe symptoms that last longer. Changes along this
direction resemble differences between adult and aged
mice [31], supporting the biological significance of this
direction.
The second direction d2 = d2(α) (Figure 4a) corre-
sponds to onset dynamics which occur in the first two
days of infection; virus that quickly reaches a high viral
load corresponds to earlier symptoms than with those
with a viral load that is slower to peak. Correlation
between time of viral and symptoms peak was observed
between the different experimental studies [23,24,34,36],
as well as between individual volunteers in an H3N2
study [52].
The response surfaces can be represented as arrays (see
the Additional file 1) that provide a fast and efficient way
to evaluate infection response. Figure 5 shows examples
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Figure 3 Ensemble model trajectories with median (black), 25-75 quartile ranges (dark gray) and 5-95 quartile ranges (light gray) across a
random sub-sample of 15,000 parameter sets from the posterior distribution.




















































































































Figure 4 Variability of host-level model responses along principal directions of the ensemble. (a) d1 and (b) d2 (Equations 7 and 8). Black
represents the best fit baseline set, red and magenta colored curves represent positive scalar values, and blue and cyan curves represent negative
scalar values. Curves are evaluated from a random sub-sample of 500 parameter sets in our posterior distribution. The dark center line of each
trajectory is the median, with the 16-85’th percentiles shaded (representing the 69% center values).
of the computed response surfaces, which are generated
by fixing lines along the 4 edges and 2 centerlines of
the response surface domain and evaluating Equation 6
(with coefficients taken from tables in Additional file 1:
Methods) for points along each fixed line in Figure 5. Posi-
tion on the response surface is described by coordinates
(x1, x2) ∈ [0, 1]× [0, 1], where the point (0.5, 0.5) corre-
sponds to the nominal case (origin of the hyper-plane)
associated with the data fitting. Along each line, we fix one
scalar value xj, j = 1, 2 and select the other scalar value
randomly from a uniform distribution. We repeat this for
35 random trajectories on each line, at xj = 0 (blue),
xj = 0.5 (red) and xj = 1.0 (green) for j = 1 (Figure 5a)
and j = 2 (Figure 5b).
Within-host epidemiological parameters derived in a
population-level model
As a starting point for the full population-scale model, we
assign two uniform random numbers (xj ∈ U(0, 1), j =
1, 2) to every individual in the population that becomes
infected. These numbers correspond to coordinates in
the response plane and are used to compute trajectories







































































Figure 5 Variability of host-level response across the response surface. The colored trajectories in (a) and (b) correspond to points on the
response surface located on equally colored lines shown in (c). The surface is parametrized by the coordinates (x1, x2) ∈ [0, 1] × [0, 1]. (The point
(0.5, 0.5) corresponds to the nominal case). The solid black lines represent thresholds above which individuals are assumed to be infectious or
symptomatic.
describing infectivity and symptomaticity of that agent
during infection. We assume infection is symptomatic
only if the respective trajectory is above a scalar threshold
value, which also provide a metric for estimating the dura-
tion of latent and incubation periods in the model. The
threshold values can be varied according to the particular
purpose of the model, as we illustrate in the age-severity
study below. Sample thresholds are plotted in Figure 5 as
solid black lines.
Symptoms are assigned values 0 (asymptomatic) if
below the threshold value or 1 (symptomatic) if above. The
symptoms threshold S∗ = 0.717 is selected so that 33% of
individuals fall below it in order to maintain a percentage
of asymptomatic cases consistent with literature estimates
[37]. The viral load threshold is selected at V ∗ = 1.35,
which gives a mean duration of infectivity of 5.2 days. The
mean onset to infectivity calculated from evaluating the
response surfaces is 0.83 days. This threshold was selected
so the model would be comparable with estimates in the
literature, and a comparison is found in the Discussion
[6,30,43,53-59].
The length of onset and duration periods are esti-
mated by interpolating where the evaluated trajectories
crosses the threshold line and the means are reported
in Table 2. Histograms representing the distributions of
times of onset and duration of infectiousness and symp-
toms, as well as time of peak symptoms and infectivity and
corresponding values are shown in Figure 6 for response
surface evaluations corresponding to one million random
numbers (infected individuals). We separate the asymp-
tomatic cases (maximum symptoms score < 0.717) and
show them in red, while symptomatic cases are in blue.
The maximum infectivity over all infections is 3.71 (com-
pared to the maximum infectivity data point of 2.88 log10
TCID50), which we use as a linear coefficient to normalize
computed viral load into transmission probability in the
agent-based simulation. We refer to the above described
within-host model as the “baseline” model, and cali-
bration of the baseline case is discussed in the Additional
file 1.
Comparison of the baseline model with a reference ABM
within-host model
We first show that the baseline within-host model pro-
duces similar results to a standard within-host model used
in ABM studies, which we call the “reference” ABMmodel
[4,10]. In the reference within-host model in FRED, the
mean duration of infectivity (4.1 days) and mean latent
period (1.2 days) can be evaluated directly using the dis-






0.83 (0.40) 0.69 (0.35) 1.11 (0.34)
Incubation
period (days)
- 2.14 (0.53) None
Duration of
infectivity (days)
5.17 (1.54) 5.87 (1.38) 3.71 ( 0.47)
Duration of
symptoms (days)
4.18 (2.32) 4.18 (2.32) None
Peak infectivity
time (days)
2.10 (0.51) 2.00 (0.51) 2.29 (0.45)
Peak infectivity
value
3.15 (0.31) 3.30 (0.22) 2.85 (0.23)
Peak symptoms
time (days)
3.04 (0.58) 2.97 (0.60) 3.19 (0.51)
Peak symptoms
score
0.86 (0.25) 0.99 (0.20) 0.60 (0.075)
We estimate epidemiological parameters pertaining to duration and intensity of
infectivity and symptoms by taking the average over 1 million randomly
generated individuals, and assume all individuals have equal probability of same
response to infection. We compute the average times for onset and resolution of
infectivity and symptoms by computing when the trajectory crosses the
thresholds S* and I* using linear interpolation, using symptoms threshold of
S* = 0.717 and viral threshold of I* = 1.35.
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(a) (b)
Figure 6 Histograms showing distribution of onset, duration, and peak of infectivity and symptoms. Histograms represent distributions
across 1 million random numbers (representing infected individuals), evaluated on the response surface (Equation 6). Asymptomatic individuals
(maximum symptoms score < 0.717) are shown in blue, while symptomatic individuals are in red. (a) Onset and duration of infectivity and
symptoms are computed from each response surface evaluation. (b) Time and value of infectivity and symptoms at their peak.
crete probability distributions explicitly used in themodel,
and give an average total duration of infection as 5.3 days
from inoculation to resolution [4]. Each infected agent is
either symptomatic or not, based on a Bernoulli random
variable.
In both cases in this comparison, all individuals who
become infectious have an equal probability of contract-
ing the same response, meaning that when an individual
becomes infected they are assigned random numbers to
represent illness independent of information such as a
demographic or pre-existing conditions. Therefore the
observed epidemiological differences are due only to the
differences in the models of within-host response. The
main difference between the two within-host models is
that symptomatic individuals have a higher infectivity last-
ing over a shorter period and asymptomatic individuals
have a lower infectivity lasting over a longer period in the
reference ABM within-host model, compared to the new
baseline within-host model.
To measure the differences resulting from the two
within-host models in a population-level simulation, we
run each epidemic scenario with 50 distinct random
seeds, and compare epidemiological measurements in
Table 3. We observe that the peak incidence correspond-
ing to the baseline within-host model occurs earlier than
the reference model (31.1 days compared to 25.1 days),
which can be attributed to the shorter incubation period
and reduced transmission rates in symptomatic individu-
als. Also observed is a larger peak incidence in the baseline
case (36,811 compared to 41,883 infected), attributed to
longer duration of infection. The reproductive rate R0
is estimated by the average number of secondary infec-
tions from the original 100 exposed individuals on day
0 computed on day 10. We observe that R0 is slightly
higher in the baseline at 2.14+0.38 than default FRED at
1.98+0.37. We measure the average time to run one simu-
lation over 100 days, and find that the Baseline case has an
average run time of 79 seconds and in the standard ABM
model has an average run time of 80 seconds on a laptop.
Age-severity study
Aging alters both the innate and adaptive branches of the
immune system, influencing response to influenza virus
infection [60]. We assume that age of an infected indi-
vidual maps to a scalar input value along d1, reflecting
longer and more severe infection and symptoms in older
individuals. To illustrate the flexibility of our immune-
epidemiological approach, we conduct a study where we
compare the simulated epidemics between three different
Table 3 Comparison of epidemiological parameters
between reference ABMmodel and baseline
Reference ABM (st.d.) Baseline (st.d.)
Attack rate (AR) 49.6588 (0.105) 50.024 (0.109)
Symptomatic AR 33.271 (0.0879) 33.6062 (0.083)
% Symptomatic 67.00% 67.18%
R0 2.14 (0.38) 1.98 (0.37)
Peak incidence (Days) 31.12 25.10
Peak incidence (# People) 36,811 41,883
Average run time 80 seconds 79 seconds
Computed parameters are presented as averages (standard deviations) from 50
population-level simulations of influenza epidemics for the ‘Reference” FRED
within-host model and the “Baseline” within-host model proposed in this
manuscript.
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age-severity maps: a linear increasing function, and two
functions based on mortality data from past epidemics
in 1918 and 1957 [61]. Mortality patterns associated with
epidemics traditionally form a “U” curve, reflecting higher
mortality and more severe disease in the very young and
the elderly. A distinctive feature of the 1918-19 influenza
pandemic was a “W” shaped pattern in the mortality
curve, showing a secondary peak in mortality rate for the
25-35 years age group [62,63]. The age-severity model
thus assumes mortality rates are indicators of severity
of disease experienced by different age groups. Piece-
wise linear functions map age to [0, 1] for all three maps,
and mortality data is scaled so the area under all three
curves (for age ∈ [0, 100]) is preserved. In this way
the model considers two factors linking age with disease
severity: deterioration of the immune system with age and
immunological memory. Immunological memory refers
to the adaptive immune response to pathogen the body
has previously encountered, and contributes to explaining
the “W” shape in the 1918 pandemic mortality curve [64].
The median age in the United States is 37.2 years, while
Allegheny County has a median age of 41.3 [65], among
the oldest in the nation. Franklin County, Ohio is compa-
rable to Allegheny in population size, density and house-
hold size (see Table 4), but has a younger age distribution
(median age 33.4). The age-severity model is also stud-
ied on Franklin County in order to compare how different
age distributions affect the overall epidemic. Plots of the
three “age-to-phenotype” maps superimposed over age
distribution histograms for both counties are presented
Figure 7(a)-(b).
Epidemiological estimates averaged across 50 random
simulations are reported in Table 5. In the baseline sce-
nario, the higher attack rate in Franklin County illus-
trates the role age distribution has on the outcome of an
epidemic (Figure 7(c)). Younger individuals, particularly
school aged, have higher contact probabilities than older
individuals. This is supported by decreased attack rates in
both counties when the age-severity models are imposed.
Across the three age-severity models, the W-curve sever-
itymodel has the highest attack rate, illustrating howmore
severe and prolonged illness in the 25-35 age group can
increase epidemic severity compared to either the linear
Table 4 Summary of demographics
Allegheny County Franklin County
Population size 1,164,879 1,069,386
Land area (miles2) 730.07 532.19
Median age 41.3 33.4
Average household size 2.23 2.38
Comparison of demographic values between Allegheny County, Pennsylvania
and Franklin County, Ohio. Source: US Census Bureau [66].
or U-shaped model. The differences between the linear
and the U-shapedmodels are less dramatic, particularly in
Allegheny County.
We plot the fold difference in the attack rates in the
age-severity models to their baselines in order to make a
direct comparison between the models (Figure 7(d)). We
observe a larger fold change for theW-model in Allegheny
County, showing that for these counties, the decreased
illness severity in the 45-65 ranges has a larger impact
than the increased illness severity in the 25-35 age range.
The larger fold change in the linear and U-shaped mod-
els of Franklin County implies a more dramatic change
in epidemic outcome when age-severity assumptions are
made in the younger age distribution scenario. The model
assumes symptomatic cases by determining threshold
maximum symptoms score. Less severe illness is more
likely to correspond to asymptomatic cases, so the age-
severity model also has tendencies to have an age depen-
dence on symptomatic cases. We report the percentage of
symptomatic patients in each scenario in Table 5.
Discussion
The strategy for incorporating the host-level model
described here could be employed with other deter-
ministic population level models as well as other well-
established ABM simulation platforms such as EpiSimS
[3]. Our aim here is to develop a methodology to bridge
the gap between within-host models of virus/symptoms
dynamics and population-level models that may also cap-
ture humanmovement and demographics. FRED provides
a ready to use framework for population-level model-
ing using the synthetic population data set, allowing easy
extension of the within-host model to simulations of pop-
ulations with different demographic descriptions (here
by distribution of age). We note that integration of our
within-host model into a deterministic population level
model may have similar results with less complexity, and
we provide the coefficients for the response surfaces in the
supplemental for straightforward use.
Our model implicitly uses age-structured contact pat-
terns in the synthetic data set and ABM, and the
results from the age-severity study reflect this relation-
ship between distribution of age and epidemic severity.
Previous studies have derived location specific contact
matrices, either through use of synthetic populations with
ABM network structures [67,68], or from surveys of Euro-
pean communities [69]. In these cases, two mixing pat-
terns emerge: a strong contact structure between people
of similar age and a weaker structure between children
and middle-aged adults, most likely due to parent-child
contact. Use of contact matrices based on social networks
better capture age-specific infection patterns of infectious
diseases which helps in estimation of the basic reproduc-
tive number R0. In our age-severity study, we provide a
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Figure 7 Age-severity study results. Panels (a) and (b) show age-distribution of population in two counties (left axis). Superimposed are three
age-severity models showing the assigned value of x1 coordinate as a function of age. (c) Attack rates for each scenario. (d) Fold change from the
baseline model for each age-severity model.
Table 5 Attack rates, reproductive number R0, and percent
symptomatic for Allegheny and Franklin Counties
Baseline Linear ‘U’ curve ‘W’ curve
AR: Allegheny
County (PA)
50.02 (0.11) 43.87 (0.15) 42.66 (0.10) 45.11 (0.12)
AR: Franklin
County (OH)
54.84 (0.11) 46.28 (0.12) 45.98 (0.13) 40.43 (0.11)
R0: Allegheny
County (PA)
2.14 (0.38) 1.92 (0.32) 1.93 (0.28) 2.00 (0.33)
R0: Franklin
County (OH)
2.28 (0.34) 2.05 (0.29) 2.05 (0.27) 2.16 (0.30)
%S: Allegheny
County (PA)
67% 54.23% 49.25% 62.16%
%S: Franklin
County (OH)
67% 48.21% 44.69% 63.16%
Comparison of simulated epidemic outcomes between the baseline model and
three age-severity models. All averages and standard deviations are computed
over 50 random simulations.
method to further fine-tune these estimates depending on
host-response to a circulating strain. The computed val-
ues of R0 in this study are derived from assumptions about
one particular experimental strain, and results may vary
depending on characteristics unique to different circulat-
ing strains.
When integrating our derived within-host model into
the population-level framework of FRED, further assump-
tions were required on scaling and thresholds. The symp-
toms threshold was set so approximately 1/3 of individuals
in the baseline scenario are asymptomatic, consistent with
accepted public health estimates [37]. However, for the
infectivity threshold I∗, there was flexibility. Different val-
ues of I∗, correspond to different latent periods, impacting
the duration of time an individual is in the exposed cat-
egory. The threshold (1.35) was selected such that the
average baseline latent periods are 0.83 days, and mean
duration of infectivity is 5.17 days. Estimates for latent
period are experimentally unknown due to difficulty in
Lukens et al. BMC Public Health 2014, 14:1019 Page 12 of 15
http://www.biomedcentral.com/1471-2458/14/1019
measuring, but a mathematical model predicts 0.4-1.5
days [53]. Duration of infectivity has been estimated at 4.8
days [37], and various studies have reported estimates at
3.38 days [30], 6.6 days [54], 5.0 days [55], and 3.1 days
[43]. Our mean value of 4.98 days thus is consistent with
existing estimates. This assumption reflects that in the
baseline model, the incubation period exceeds the latent
period, so there is a period in which an individual is not
symptomatic and shedding virus. In one modeling study, a
lag of 1.9 days between latent and incubation periods was
assumed [6].
In our study, the incubation period is estimated at 2.14
days, duration of symptoms about 4 days for the symp-
tomatic cases, in which both estimates rely on our choice
of symptoms threshold. Incubation period has been esti-
mated anywhere from 1.4 days (1.3 - 1.5 95% CI) [56],
1.5-2 days [57], 2-3 days [58], to 4 days [30]. Estimates for
duration of symptoms vary from 4.5-5 days [37], 6 days
[59], 5.6 days [55]. We remark that lowering the symp-
toms threshold would coincide with a shorter incubation
period. One estimate that is well agreed upon is that viral
load peaks at around 2 days post inoculation, and symp-
toms peak at around 3 days p.i. [37], which is consistent
with our simulation measurements as well.
We selected the mathematical model of Baccam et al.
[38] to describe viral and symptoms dynamics for three
reasons. First, structural identifiability analysis showed
parameter values could be estimated given the data. Sec-
ond, it is the simplest model that generated the required
inputs for a population level simulation (infectivity and
symptoms score), and last, the model fit the data. Our
method also provides a method for varying host-level
responses from experimental baseline measurements in
order to predict various illness scenarios under different
host assumptions. As a starting point, we used a nominal
response calibrated to one non-pandemic seasonal human
influenza strain (A/Texas/36/91). As more data allows
more subtle description of disease phenotypes character-
ized by more complex within-host models, our method
could be easily scaled to such models as, although compu-
tation of the response-surfaces is more complex, it is done
a priori and thus requires no additional resources for the
population-level simulation.
Community based studies also give insight correspond-
ing to our assumption that infection in the elderly may be
characterized by longer viral load, and longer and higher
symptoms scores. One study suggests a median dura-
tion of symptoms of 7 days for the entire community,
compared to 8 days for older people [30]. Another study
estimates that duration of infectiousness/viral shedding is
6.3 days for children, and 6.7 days for adults [54]. Using
a linear mapping from age to infection severity is a sim-
plistic assumption without biological motivation, which is
why three different mappings were studied.
Our model estimates of duration and intensity of
infectivity and symptoms show asymptomatic infec-
tions correspond to reduced viral load, which is con-
sistent with previous studies of asymptomatic disease
and transmission, but the degree is unknown [70]. In a
community-based study of 2009 H1N1 in Hong Kong,
peak viral load averaged over the asymptomatic subjects
was 3.2e3 copies/mL compared to 3.6e7 copies/mL aver-
aged over the symptomatic subjects [57]. In a recent
human volunteer study of H3N2/Wisconsin, 50% of
asymptomatic subjects had evident viral shedding and a
reported a significantly reduced viral load in the asymp-
tomatic cases [52]. However, the exact mechanism con-
tributing to asymptomatic infection is not incorporated
in this model, and a study of these mechanisms and
how they influence an epidemic are important future
considerations.
This study makes the assumption that infectivity scales
linearly with contact rate and is proportional to the
log10 of the viral load as measured by nasopharyngeal
swabs. Although this is plausible, the exact relationship
between viral load and infectivity on disease transmis-
sion is unknown. One model, which studies the relation-
ship between virus/host dynamics and a population-level
model, multiplied viral load by the amount of nasal dis-
charge as the estimate of infectivity [71]. Another model
of measles used the area under the infected cell curve
to model transmission strength by ‘amount’ of infection
which was also used as a determinant for symptomatic
or asymptomatic infection [72]. In a household study of
influenza transmission in Hong Kong, models of molec-
ular viral shedding and log10 molecular viral shedding
were studied to compare viral load with transmission [57].
The case in which viral load is used as an indicator of
transmission leads to nearly all transmission occurring in
the first 1-2 days after inoculation, implying that inter-
vention strategies must be rapid. Using the log10 model
of viral shedding to transmission corresponds to signif-
icant transmission lasting strongly up to 3-4 days after
viral inoculation. Therefore, knowing the exact relation-
ship between infectivity and disease transmission would
improve modeling and have significant implication for
mitigation strategies.
In the mathematical model describing the host immune
response, symptoms scores are generated from the bio-
logical mechanisms described by the ODE model, which
greatly simplifies complex immune system dynamics. The
immune system is composed of innate and adaptive com-
ponents, which respond to viral infection through inflam-
mation and creation of virus-specific antibodies and
effector cells to help resolve the infection [73]. Previous
models have been studied within the context of improved
understanding of population-level dynamics have incor-
porated interactions of the innate immune system
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[53,74]. Incorporating features such as inflammation and
virus-specific antibody production would yield more real-
istic within-host dynamics, and could explicitly account
for factors such as preexisting immunity. Importantly,
more complex models could be attempted using response
surface methodology at little additional computational
cost for large-scale simulations. Further, the ensemble
methodology allows the computation of the thickness
of the response surface, which would add an additional
stochastic element better representing our incomplete
knowledge of individual responses.
The added flexibility of a mechanistic within-host to
population-level models might be particularly relevant
when evaluating the impact of host-level containment
measures and additional factors known to demonstrate
significant within-host effect depending on immune sta-
tus. The ability to include this flexibility at minimal
computational cost also offers exiting possibilities when
simulating new variants, co-infection with bacterial
pathogens, for providing a biological basis for morbidity,
undoubtedly a major driver of agent behavior and cost
of disease, and for mortality related to disease, which is
currently lacking in existing population-level simulators.
Conclusions
We have developed a multi-scale immuno-epidemiological
ABMmodel linking an equation-based within-host model
to an agent-based population level model. The key inno-
vation is the use of response surface analysis to simplify
the computation of output trajectories of the equation-
based within-host model, which makes the immuno-
epidemiological model just as efficient and scalable as
the underlying population-level ABM. The hybrid ABM
model replicates results of simulated epidemics with sim-
pler within-host assumptions such as the reference FRED
within-host model, and provides additional flexibility to
explore questions relevant to host heterogeneity at no
extra computational cost.
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